Date | Title | Description | |
---|---|---|---|
24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
09 Jul 2020 | On business and financial situation | ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate | Download |
Pages
Date | Title | Description | |
---|---|---|---|
28 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 23 February 2022 and 25 February 2022 | Download |
23 Feb 2022 | Annual Corporate Governance Report | ROVI releases the 2021 Annual Corporate Governance Report | Download |
23 Feb 2022 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2021 annual report regarding remuneration of the members of the Board of Directors | Download |
21 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 | Download |
15 Feb 2022 | On business and financial situation | ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. | Download |
Pages
Date | Title | Description | |
---|---|---|---|
18 Nov 2015 | Convocatorias y acuerdos de Juntas y Asambleas generales | Download | |
22 Oct 2015 | información sobre resultados | Download | |
22 Oct 2015 | información sobre resultados (2) | Download | |
21 Oct 2015 | Otros sobre Gobierno Corporativo | Download | |
16 Oct 2015 | Convocatorias y Acuerdos de Juntas y Asambleas Generales | Download |